Progressive Sarcopenia Correlates with Poor Response and Outcome to Immune Checkpoint Inhibitor Therapy

Progressive Sarcopenia Correlates with Poor Response and Outcome to Immune Checkpoint Inhibitor Therapy

Background<strong>: </strong>Immune checkpoint inhibitors (ICIs) represent a new therapeutic standard for an increasing number of tumor entities. Nevertheless, individual response and outcome to ICI is very heterogeneous, and the identification of the ideal ICI candidate has remained one...

Full description

Bibliographic Details
Main Authors: Sven H. H. Loosen, Vincent van den Bosch, Joao Gorgulho, Maximilian Schulze-Hagen, Jennis Kandler, Markus S. S. Jördens, Frank Tacke, Christina Loberg, Gerald Antoch, Tim Brümmendorf, Ulf P. Neumann, Christiane Kuhl, Tom Luedde, Christoph Roderburg
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Journal of Clinical Medicine
Subjects:
sarcopenia
checkpoint inhibitors
ICI
PD-L1
PD-1
prognosis
Online Access:https://www.mdpi.com/2077-0383/10/7/1361

Internet

https://www.mdpi.com/2077-0383/10/7/1361

Similar Items